Therapy Areas: Autoimmune
Kyverna Therapeutics signs license and supply agreement with Oxford Biomedica
21 September 2023 - Kyverna Therapeutics, a California-based clinical-stage cell therapy company, announced on Wednesday that it has signed a non-exclusive, multi-year license and supply agreement wit...
Everest Medicines signs collaboration and license agreement with Kezar Life Sciences
21 September 2023 - Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Wednesday that it has signed a collaboration and license agreement with Kezar Life Sciences,...
Pfizer's LITFULO gains EC approval for treating severe alopecia areata in adolescents and adults
19 September 2023 - Biopharmaceutical company Pfizer Inc (NYSE: PFE) announced on Tuesday that it has received European Commission (EC) marketing authorisation for LITFULO (ritlecitinib) to treat seve...
Q32 Bio doses first subject in Bempikibart proof-of-concept study
14 September 2023 - Q32 Bio, a clinical stage biotechnology company, and Horizon Therapeutics plc (Nasdaq: HZNP), a biopharmaceutical company, announced on Wednesday that the first subject has been do...
FDA grants Orphan Drug Designation to Cantargia's CAN10 for systemic sclerosis treatment
6 September 2023 - Swedish biotechnology company Cantargia AB (STO:CANTA) said on Wednesday that it has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for CAN10 in the...
Alpine Immune Sciences announces presentation of preclinical data for povetacicept in myasthenia gravis at ANA Annual Meeting
5 September 2023 - Immunotherapy company Alpine Immune Sciences (NASDAQ: ALPN)announced on Tuesday that it will present new preclinical data on povetacicept for myasthenia gravis at the 148th Annual A...